Abbvie Inc NYSE:ABBV:
ABBVIE ANNOUNCES TEPKINLY® (EPCORITAMAB) IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IS APPROVED BY THE EUROPEAN COMMISSION FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Reuters
Abbvie Says Tepkinly In Combination With Lenalidomide And Rituximab Approved By European Commission
- Sources
- Reuters
- Markets
- ETFs
- Active symbols
- NYSE:ABBV
- Language
- English
Abbvie Inc NYSE:ABBV: